{"id":"NCT01682759","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)","officialTitle":"A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-09-10","primaryCompletion":"2015-01-26","completion":"2015-01-26","firstPosted":"2012-09-11","resultsPosted":"2016-02-05","lastUpdate":"2018-09-07"},"enrollment":751,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Omarigliptin","otherNames":[]},{"type":"DRUG","name":"Placebo to Omarigliptin","otherNames":[]},{"type":"DRUG","name":"Glimepiride","otherNames":["AMARYLÂ®","GLIMY"]},{"type":"DRUG","name":"Glimepiride Placebo","otherNames":[]},{"type":"DRUG","name":"Metformin","otherNames":[]},{"type":"DRUG","name":"Insulin Glargine","otherNames":[]}],"arms":[{"label":"Omarigliptin","type":"EXPERIMENTAL"},{"label":"Glimepiride","type":"ACTIVE_COMPARATOR"}],"summary":"This trial will assess the safety and efficacy of omarigliptin (MK-3102) compared with the sulfonylurea, glimepiride, in Type 2 diabetes mellitus participants with inadequate glycemic control on metformin monotherapy. The primay hypothesis of the study is that after 54 weeks, the mean change from baseline in hemoglobin A1C (A1C) in participants treated with omarigliptin is non-inferior compared with that in participants treated with glimepiride.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1C at Week 54","timeFrame":"Baseline and Week 54","effectByArm":[{"arm":"Omarigliptin","deltaMin":-0.3,"sd":null},{"arm":"Glimepiride","deltaMin":-0.48,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":9},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28548024"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":375},"commonTop":["Hypoglycaemia","Nasopharyngitis"]}}